Assignee
XINTELA AB
SE·12 granted patents·5 pending applications·23 citations·filing 2003–2024
Top patents by PatentIndex Score
17 records- 0183US10087253B2Monoclonal antibody capable of binding integrin alpha 10 beta 1XINTELA AB·Filed 2016·Granted Oct 2, 2018·5 cites·10 claims
- 0282US8048991B2Antibody to an integrin heterodimer and/or a subunit thereofXINTELA AB·Filed 2006·Granted Nov 1, 2011·9 cites·10 claims
- 0378US8012696B2Monoclonal antibody capable of binding integrin alpha 10 beta 1XINTELA AB·Filed 2008·Granted Sep 6, 2011·3 cites·6 claims
- 0477US8895253B2Integrin heterodimer and a subunit thereofXINTELA AB·Filed 2012·Granted Nov 25, 2014·2 cites·18 claims
- 0575US12247222B2Quality assurance of chondrocytesXINTELA AB·Filed 2023·Granted Mar 11, 2025·0 cites·21 claims
- 0674US2025020646A1Marker for Neural Stem CellsXINTELA AB·Filed 2024·Application pending·0 cites
- 0766US10081666B2Integrin heterodimer and a subunit thereofXINTELA AB·Filed 2014·Granted Sep 25, 2018·0 cites·12 claims
- 0865US11725188B2Quality assurance of chondrocytesXINTELA AB·Filed 2020·Granted Aug 15, 2023·0 cites·15 claims
- 0963US10781424B2Quality assurance of chondrocytesXINTELA AB·Filed 2019·Granted Sep 22, 2020·0 cites·9 claims
- 1063US7749710B2Marker for stem cells and its useXINTELA AB·Filed 2003·Granted Jul 6, 2010·4 cites·20 claims
- 1161US9365649B2Monoclonal antibody capable of binding integrin alpha 10 beta 1XINTELA AB·Filed 2013·Granted Jun 14, 2016·0 cites·6 claims
- 1258US11517593B2Prevention and treatment of bone and cartilage damage or diseaseXINTELA AB·Filed 2019·Granted Dec 6, 2022·0 cites·18 claims
- 1357US2021316005A1Detection and Treatment of Malignant Tumours in the CNSXINTELA AB·Filed 2021·Application pending·0 cites
- 1457US2023128397A1Prevention and treatment of bone and cartilage damage or diseaseXINTELA AB·Filed 2022·Application pending·0 cites
- 1550US10994022B2Detection and treatment of malignant tumours in the CNSXINTELA AB·Filed 2016·Granted May 4, 2021·0 cites·22 claims
- 1643US2023346843A1Stem Cells for Treatment of Respiratory DisordersXINTELA AB·Filed 2021·Application pending·0 cites
- 1740US2019369093A1Marker for Neural Stem CellsXINTELA AB·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XINTELA AB files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →